Related Experiment Videos
Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant
1Division of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Surgery
|September 20, 2001
Summary
Biodegradable microspheres loaded with interleukin-12 (IL-12) effectively suppress tumor growth and metastasis. This immunotherapy shows promise as a neoadjuvant treatment, reducing recurrence rates.
Area of Science:
- Oncology
- Immunotherapy
- Biomaterials
Background:
- Previous studies showed intratumoral interleukin-12 (IL-12) microsphere injection induces systemic antitumor immunity.
- Investigated the potential of IL-12 microspheres as neoadjuvant therapy.
Purpose of the Study:
- To evaluate the efficacy of IL-12-loaded polylactic acid microspheres as a neoadjuvant therapy.
- To assess the impact on tumor growth, metastasis, and recurrence rates.
Main Methods:
- Mice received intratumoral injections of IL-12 or BSA-loaded microspheres.
- Tumor growth, pulmonary metastases, and local recurrence were assessed post-treatment and post-resection.
Main Results:
- IL-12 microspheres significantly suppressed tumor growth and reduced pulmonary metastases compared to controls.
- Neoadjuvant IL-12 microsphere therapy decreased local recurrence and pulmonary metastases.
- Earlier tumor resection did not improve outcomes.
Conclusions:
- Intratumoral IL-12 microspheres promote systemic antitumor immunity and eradicate micrometastases.
- IL-12 microspheres are effective as neoadjuvant therapy, reducing local and distant recurrence.